查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1603576

轴型脊椎关节炎 (axSpA) 市场报告：2030 年趋势、预测和竞争分析

Axial Spondyloarthritis (AXSPA) Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

中轴型脊椎关节炎 (axSpA) 的趋势和预测

全球中轴型脊椎关节炎（axSpA）市场未来性，非类固醇消炎剂（NSAID）、糖皮质激素和抗风湿药市场充满机会。到 2030 年，全球中轴型脊椎关节炎 (axSpA) 市场预计将达到 96 亿美元，2024 年至 2030 年复合年增长率为 6.5%。该市场的主要驱动因素是人口迅速老化、脊椎关节炎盛行率增加以及製药公司为开发有效治疗方法而活性化的研发活动。

  • Lucintel 预测，按类型划分，僵直性脊椎炎(AS) 将在预测期内成长最快。
  • 按药物类别划分，非类固醇消炎剂(NSAID) 预计成长最快，因为它们可以缓解术后疼痛，并且通常由医生处方。
  • 从地区来看，由于认识的提高和盛行率的上升，预计北美在预测期内将经历最高的增长。

中轴型脊椎关节炎 (axSpA) 市场的策略性成长机会

中轴型脊椎关节炎 (axSpA) 市场在各种应用中提供了多种策略性成长机会。识别和利用这些机会可以推动市场扩张和创新：

  • 儿科治疗：开拓治疗儿童腋窝脊椎炎的特定年龄配方，为满足具有独特需求的特殊患者群体提供了机会，最终扩大了市场。
  • 早期诊断与早期疗育：先进的诊断工具能够及早发现 axSpA，从而改善患者的治疗效果并显着降低长期医疗费用。
  • 获得农村医疗保健：在农村和服务欠缺地区利用远端医疗和行动医疗单位可以改善获得 axSpA 治疗的机会，并提高都市区卫生系统的有效性，我们可以缩小差距并缩小健康差距。
  • 老年病学：越来越多的老年人容易患上 axSpA 等肌肉骨骼疾病，这将增加对标靶治疗的需求，并为老年病学提供新的机会。
  • COVID-19 后治疗：解决 COVID-19 引起的长期肌肉骨骼併发症为 axSpA 治疗提供了一个新的细分市场，在改善患者治疗效果的同时提供成长潜力。

这些成长机会正在推动 axSpA 市场的创新和市场扩张。透过技术进步满足患者的各种需求，市场可以实现持续成长。

中轴型脊椎关节炎（axSpA）市场驱动因素与挑战

中轴型脊椎关节炎 (axSpA) 市场受到各种技术、经济和监管因素的影响。了解这些市场驱动因素和挑战对于利用市场的动态性质并取得财务成功至关重要。

axSpA 市场的关键驱动因素是：

1.技术进步：先进诊断工具和数位健康技术等技术创新使 axSpA 治疗更易于管理，并有助于市场成长。

2.2. axSpA 盛行率不断增加：受 axSpA 影响的患者数量不断增加，需要有效的治疗方案，从而推动市场成长并刺激该领域的进一步创新。

3.人口老化：随着世界人口老化，axSpA等肌肉骨骼疾病的盛行率不断增加，增加了治疗需求并促进了市场成长。

4. 政府措施：政府改善医疗基础设施和增加 axSpA 治疗机会的措施正在推动需求，特别是在新兴国家。

5.加大研发投入：製药公司和政府正在加大研发投入，带动axSpA市场新治疗方法和创新的发展。

axSpA 市场面临的挑战是：

1.治疗成本高：先进治疗方法（尤其是生物製药）的高治疗成本可能会限制患者获得治疗并阻碍市场成长。

2. 监管障碍：严格的监管要求和漫长的核准流程可能会减缓新治疗方法的推出并影响市场成长。

3.市场竞争：学名药和替代疗法的激烈竞争给价格和市场占有率带来压力，迫使主要企业不断创新以维持自己的地位。

这些市场驱动因素和挑战塑造了市场动态。寻求在这一竞争格局中取得成功的公司必须了解这些因素，才能有效驾驭市场格局。

目录

第一章执行摘要

第二章全球中轴型脊椎关节炎 (axSpA) 市场：市场动态

  • 简介、背景、分类
  • 供应链
  • 产业驱动因素与挑战

第三章 2018-2030年市场趋势及预测分析

  • 宏观经济趋势（2018-2023）与预测（2024-2030）
  • 全球中轴型脊椎关节炎（axSpA）市场趋势（2018-2023）与预测（2024-2030）
  • 全球中轴型脊椎关节炎 (axSpA) 市场（按类型）
    • 僵直性脊椎炎（AS）
    • 非放射性中轴型脊椎关节炎 (nr-axSpA)
  • 全球中轴型脊椎关节炎 (axSpA) 市场（按药物类别）
    • 非类固醇消炎剂(NSAID)
    • 糖皮质激素
    • 抗风湿药
    • 其他的

第四章 2018-2030年区域市场趋势及预测分析

  • 按地区分類的全球中轴型脊椎关节炎 (axSpA) 市场
  • 北美中轴型脊椎关节炎 (axSpA) 市场
  • 欧洲中轴型脊椎关节炎（axSpA）市场
  • 亚太地区中轴型脊椎关节炎 (axSpA) 市场
  • 其他地区中轴型脊椎关节炎（axSpA）市场

第五章 竞争分析

  • 产品系列分析
  • 营运整合
  • 波特五力分析

第六章 成长机会与策略分析

  • 成长机会分析
    • 按类型分類的全球中轴型脊椎关节炎 (axSpA) 市场成长机会
    • 按药物类别分類的全球中轴型脊椎关节炎 (axSpA) 市场成长机会
    • 全球中轴型脊椎关节炎 (axSpA) 市场成长机会（按地区）
  • 全球中轴型脊椎关节炎 (axSpA) 市场的新兴趋势
  • 战略分析
    • 新产品开发
    • 全球中轴型脊椎关节炎（axSpA）市场容量扩张
    • 全球中轴型脊椎关节炎 (axSpA) 市场的合併、收购和合资企业
    • 认证和许可

第七章主要企业概况

  • Janssen Biotech
  • AbbVie
  • UCB
  • Amgen
  • Novartis Pharmaceuticals Corporation
简介目录

Axial Spondyloarthritis (AXSPA) Trends and Forecast

The future of the global axial spondyloarthritis (AXSPA) market looks promising with opportunities in the non-steroidal anti-inflammatory drug (NSAID), glucocorticoid, and anti-rheumatic drug markets. The global axial spondyloarthritis (AXSPA) market is expected to reach an estimated $9.6 billion by 2030 with a CAGR of 6.5% from 2024 to 2030. The major drivers for this market are a surge in the aging population, the rising prevalence of spondyloarthritis, and growing research and development activities by pharmaceutical companies to develop effective treatments.

  • Lucintel forecasts that, within the type category, ankylosing spondylitis (AS) is expected to witness higher growth over the forecast period.
  • Within the drug class category, non-steroidal anti-inflammatory drug (NSAIDs) is expected to witness the highest growth due to their help to relieve pain after surgery and are mostly prescribed by doctors.
  • In terms of regions, North America is expected to witness the highest growth over the forecast period due to an increase in awareness and rising prevalence of disease.

Gain valuable insights for your business decisions with our comprehensive 150+ page report.

Emerging Trends in the Axial Spondyloarthritis (AXSPA) Market

Emerging trends in the axial spondyloarthritis (AxSpA) market are reshaping its future applications and dynamics:

  • Personalized Medicine: The adoption of personalized medicine in AxSpA is gaining popularity, guided by genomic testing, which leads to targeted therapies. This allows treatments to be tailored to individual profiles, reducing side effects and improving overall outcomes.
  • Biosimilars: The introduction and acceptance of biosimilars are increasing due to their lower cost compared to biologics. This makes treatments more accessible to a larger patient population, thereby contributing to market growth.
  • Digital Health Technologies: Digital health technologies, such as telemedicine and mobile health apps, are increasingly used in AxSpA management. These tools improve monitoring, enhance adherence to treatment plans, and provide real-time data to aid medical decision-making.
  • Combination Therapies: Combination therapies, which include several active components, are becoming more common in treating AxSpA. These formulations simplify treatment regimens, enhance patient compliance, and target multiple disease pathways, leading to improved therapeutic outcomes.
  • Patient-Centric Care: There is a growing shift toward holistic treatment approaches that focus on improving the overall quality of life for patients. Emphasis is being placed on patient education, lifestyle modifications, and comprehensive management plans that address both physical and mental health aspects.

These emerging trends are reshaping the AxSpA market, driving innovation and improving patient care. These trends will have a significant impact on market growth and direction as they continue to evolve.

Recent Developments in the Axial Spondyloarthritis (AXSPA) Market

Recent developments in the axial spondyloarthritis market include a range of innovations and advancements:

  • New Drug Approvals: The approval of new biologics and biosimilars for AxSpA is expanding the therapeutic options available to patients, leading to better treatment outcomes and improved quality of life.
  • Technological Innovations: Advancements such as improved diagnostic tools and digital health technologies are enhancing the detection and management of AxSpA, improving patient adherence to treatment regimens.
  • Strategic Collaborations: Collaborations between pharmaceutical companies, research institutions, and healthcare providers are accelerating the development of novel therapeutics, leading to improved clinical outcomes through combined expertise and resources.
  • Regulatory Advancements: Regulatory advancements, including faster approval processes and incentives for orphan drug development, are encouraging innovation in the AxSpA market, enabling quicker access to cutting-edge treatments.
  • Increased R&D Investment: Rising research and development funding from both the private sector and governments is facilitating the discovery of new therapeutic targets and the development of advanced treatments for AxSpA.

These developments are significantly influencing the AxSpA market by fostering innovation, enhancing patient outcomes, and expanding treatment options. They will play a crucial role in the market's continued expansion.

Strategic Growth Opportunities for Axial Spondyloarthritis (AXSPA) Market

The axial spondyloarthritis (AxSpA) market presents several strategic growth opportunities across various applications. Identifying and capitalizing on these opportunities can drive market expansion and innovation:

  • Pediatric Treatment: Developing age-specific formulations for treating AxSpA in children offers an opportunity to address a special patient group with unique needs, ultimately expanding the market.
  • Early Diagnosis and Intervention: Advanced diagnostic tools enable earlier detection of AxSpA, leading to better patient outcomes and significant long-term healthcare cost savings.
  • Rural Healthcare Access: The use of telemedicine and mobile healthcare units in rural and underserved areas can improve access to AxSpA treatments, bridging the gap between urban and rural healthcare systems and reducing health disparities.
  • Geriatric Care: The increasing elderly population, who are more likely to develop musculoskeletal disorders like AxSpA, creates a growing demand for targeted treatments, offering new opportunities in geriatric care.
  • Post-COVID-19 Therapeutics: Addressing long-term musculoskeletal complications resulting from COVID-19 presents a new market segment for AxSpA treatments, offering the potential for growth while also improving patient outcomes.

These growth opportunities are driving innovation and market expansion in the AxSpA market. By meeting various patient needs through technological advancements, the market can achieve sustainable growth.

Axial Spondyloarthritis (AXSPA) Market Driver and Challenges

The axial spondyloarthritis (AxSpA) market is influenced by various technological, economic, and regulatory factors. Understanding these drivers and challenges is crucial for navigating the dynamic nature of the market and achieving financial success.

The key drivers of the AxSpA market include:

1. Technological Advancements: Technological innovations, such as advanced diagnostic tools and digital health technologies, improve the ease of managing AxSpA treatments, contributing to market growth.

2. Increasing Prevalence of AxSpA: The rising number of individuals affected by AxSpA necessitates effective treatment options, driving market growth and spurring further innovation in the field.

3. Aging Population: As the global population ages, the incidence of musculoskeletal disorders like AxSpA increases, leading to higher demand for treatments and contributing to market growth.

4. Government Initiatives: Particularly in emerging economies, government efforts to improve healthcare infrastructure and increase access to AxSpA treatments are pushing up demand.

5. Increased R&D Investment: Pharmaceutical companies and governments are investing more heavily in R&D, leading to the development of new treatments and innovations in the AxSpA market.

Challenges facing the AxSpA market include:

1. High Treatment Costs: The high cost of advanced therapies, particularly biologics, can limit patient access to treatment and hinder market growth.

2. Regulatory Hurdles: Stringent regulatory requirements and lengthy approval processes can slow the introduction of new treatments, impacting market growth.

3. Market Competition: Intense competition from generic drugs and alternative therapies can put pressure on prices and market share, compelling key players to continually innovate to maintain their position.

These drivers and challenges shape the market's dynamics. Companies seeking success in this competitive industry must understand these factors to effectively navigate the market landscape.

List of Axial Spondyloarthritis (AXSPA) Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies axial spondyloarthritis (AXSPA) companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the axial spondyloarthritis (AXSPA) companies profiled in this report include-

  • Janssen Biotech
  • AbbVie
  • UCB
  • Amgen
  • Novartis Pharmaceuticals Corporation

Axial Spondyloarthritis (AXSPA) by Segment

The study includes a forecast for the global axial spondyloarthritis (AXSPA) by type, drug class, and region.

Axial Spondyloarthritis (AXSPA) Market by Type [Analysis by Value from 2018 to 2030]:

  • Ankylosing Spondylitis (AS)
  • Non-Radiographic Axial Spondyloarthritis (nr-axSpA)

Axial Spondyloarthritis (AXSPA) Market by Drug Class [Analysis by Value from 2018 to 2030]:

  • Non-Steroidal Anti-Inflammatory Drugs (NSAID)
  • Glucocorticoids
  • Anti-Rheumatic Drugs
  • Others

Axial Spondyloarthritis (AXSPA) Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

Country Wise Outlook for the Axial Spondyloarthritis (AXSPA) Market

Major players in the AxSpA market are expanding their operations and forming strategic partnerships to strengthen their positions. Below are recent developments from key regions: the USA, China, India, Japan, and Germany.

  • United States: The FDA has recently approved new biologics and biosimilars for AxSpA. There is also a growing focus on patient-centric approaches, incorporating advanced diagnostic tools that enhance early detection and enable personalized treatment plans. This has led to improved patient outcomes.
  • China: Investment in healthcare infrastructure and research in China has led to the development of advanced biologics and biosimilars for AxSpA. Government initiatives aimed at improving access to medical services have increased demand for these treatments across the population.
  • Germany: In Germany, AxSpA treatment is increasingly centered around personalized medicine, with the integration of advanced diagnostic technologies. Collaborative studies between academic institutions and pharmaceutical companies are facilitating the faster development of innovative therapies and improving clinical outcomes.
  • India: In India, cost-effective generics and biosimilars dominate the AxSpA market. Recent developments include growing awareness of AxSpA diagnosis and government initiatives aimed at improving healthcare accessibility and affordability.
  • Japan: Japan is leveraging its strong pharmaceutical infrastructure to develop next-generation biologics for AxSpA treatment. New therapies have been approved, and the integration of digital health technologies is improving patient care and management.

Features of the Global Axial Spondyloarthritis (AXSPA) Market

Market Size Estimates: Axial spondyloarthritis (axspa) market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Axial spondyloarthritis (axspa) market size by type, drug class, and region in terms of value ($B).

Regional Analysis: Axial spondyloarthritis (axspa) market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different type, drug class, and regions for the axial spondyloarthritis (axspa) market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the axial spondyloarthritis (axspa) market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the axial spondyloarthritis (axspa) market to 2030 by technology (thermal, night vision, laser rangefinder, digital storage, and others), stabilization (image stabilized and standard), application (military, astronomy, sports, hunting & shooting, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Axial Spondyloarthritis (AXSPA) Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Axial Spondyloarthritis (AXSPA) Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Axial Spondyloarthritis (AXSPA) Market by Type
    • 3.3.1: Ankylosing Spondylitis (AS)
    • 3.3.2: Non-Radiographic Axial Spondyloarthritis (nr-axSpA)
  • 3.4: Global Axial Spondyloarthritis (AXSPA) Market by Drug Class
    • 3.4.1: Non-Steroidal Anti-Inflammatory Drugs (NSAID)
    • 3.4.2: Glucocorticoids
    • 3.4.3: Anti-Rheumatic Drugs
    • 3.4.4: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Axial Spondyloarthritis (AXSPA) Market by Region
  • 4.2: North American Axial Spondyloarthritis (AXSPA) Market
    • 4.2.1: North American Market by Type: Ankylosing Spondylitis (AS) and Non-Radiographic Axial Spondyloarthritis (nr-axSpA)
    • 4.2.2: North American Market by Drug Class: Non-Steroidal Anti-Inflammatory Drugs (NSAID), Glucocorticoids, Anti-Rheumatic Drugs, and Others
  • 4.3: European Axial Spondyloarthritis (AXSPA) Market
    • 4.3.1: European Market by Type: Ankylosing Spondylitis (AS) and Non-Radiographic Axial Spondyloarthritis (nr-axSpA)
    • 4.3.2: European Market by Drug Class: Non-Steroidal Anti-Inflammatory Drugs (NSAID), Glucocorticoids, Anti-Rheumatic Drugs, and Others
  • 4.4: APAC Axial Spondyloarthritis (AXSPA) Market
    • 4.4.1: APAC Market by Type: Ankylosing Spondylitis (AS) and Non-Radiographic Axial Spondyloarthritis (nr-axSpA)
    • 4.4.2: APAC Market by Drug Class: Non-Steroidal Anti-Inflammatory Drugs (NSAID), Glucocorticoids, Anti-Rheumatic Drugs, and Others
  • 4.5: ROW Axial Spondyloarthritis (AXSPA) Market
    • 4.5.1: ROW Market by Type: Ankylosing Spondylitis (AS) and Non-Radiographic Axial Spondyloarthritis (nr-axSpA)
    • 4.5.2: ROW Market by Drug Class: Non-Steroidal Anti-Inflammatory Drugs (NSAID), Glucocorticoids, Anti-Rheumatic Drugs, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Axial Spondyloarthritis (AXSPA) Market by Type
    • 6.1.2: Growth Opportunities for the Global Axial Spondyloarthritis (AXSPA) Market by Drug Class
    • 6.1.3: Growth Opportunities for the Global Axial Spondyloarthritis (AXSPA) Market by Region
  • 6.2: Emerging Trends in the Global Axial Spondyloarthritis (AXSPA) Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Axial Spondyloarthritis (AXSPA) Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Axial Spondyloarthritis (AXSPA) Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Janssen Biotech
  • 7.2: AbbVie
  • 7.3: UCB
  • 7.4: Amgen
  • 7.5: Novartis Pharmaceuticals Corporation